anti-FGFR2b antibody · antibody
bemarituzumab
0 active trials, targeting FGFR2b. Not approved for any biomarker on marked.bio yet.
Also known as FPA144.
Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.
Biomarkers
| Biomarker | Active trials | All trials | Furthest active phase |
|---|---|---|---|
| MSI-H / dMMR | 0 | 1 | – |
Trials
0 of 1 trials shown
-
AssociatiNG Bevacizumab bEmarituzumab for GynecoLogIcal CAncer
For dMMR endometrial carcinoma : immunotherapy
MSI-H / dMMREndometrial Carcinoma, Ovarian Cancer, Cervix Cancer
No trials match these filters.